TPCW
DNTH icon

TD Private Client Wealth’s Dianthus Therapeutics DNTH Stock Holding History

TD Private Client Wealth’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17
Closed -$308 – 1443
2025
Q1 		$308 Buy
+17
New +$375 ﹤0.01% 1361

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TD Private Client Wealth's DNTH Position: Q2 2025 in Review

TD Private Client Wealth sold out of Dianthus Therapeutics (DNTH) in Q2 2025, closing a stake of 17 shares — an estimated $308 sold.

TD Private Client Wealth first reported a position in DNTH in Q1 2025 and held it in 1 quarter. The position peaked at $308 in Q1 2025. 102 funds tracked by Wall St. Rank hold DNTH as of Q2 2025.

  • TD Private Client Wealth reported no remaining Dianthus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • TD Private Client Wealth sold 17 Dianthus Therapeutics shares in Q2 2025, an estimated $308.
  • TD Private Client Wealth first reported a position in Dianthus Therapeutics in Q1 2025 and held it in 1 quarter.
  • TD Private Client Wealth's Dianthus Therapeutics position peaked at $308 in Q1 2025.
  • 102 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2025.

Based on TD Private Client Wealth's 13F filing for Q2 2025, filed 15 Jul 2025.